Loading...
01/11 03:09
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary presents a mixed picture. While there are strategic plans for 2026, current issues like the negative impact of ACO REACH program changes and unclear management responses create uncertainty. The Q&A section highlights concerns about profitability and contract renewals, but also notes potential improvements in 2026. The market cap suggests moderate volatility, leading to a neutral sentiment as the stock may not significantly move in either direction over the next two weeks.
Revenue $1.44 billion for Q3 2025, a slight decrease from $1.45 billion in Q3 2024. The year-over-year decline was due to lower-than-expected risk adjustment and the impact of market and payer contract exits.
Medical Margin Negative $57 million for Q3 2025, compared to negative $58 million in Q3 2024. The margin was impacted by elevated cost trends, lower-than-expected risk adjustment, and exited markets.
Adjusted EBITDA Negative $91 million for Q3 2025, compared to negative $96 million in Q3 2024. The improvement was due to lower geography entry costs and continued operating cost discipline.
Medicare Advantage Membership 503,000 members at the end of Q3 2025, down from 525,000 members in Q3 2024. The decline was attributed to a measured approach to membership growth and partner exits.
ACO REACH Membership 115,000 members in Q3 2025, down from 132,000 members in Q3 2024. The decline was due to partner exits and a smaller 2025 class.
Operating Cost Reduction $30 million reduction in operating costs achieved through centralization, technology implementation, and alignment with PCP partners.
Enhanced Data Pipeline: agilon has implemented an enhanced data pipeline that provides timely direct payer data feeds, validated member-level clinical and claims data, and member-level risk scores for approximately 80% of members.
Clinical Pathways: Developed in collaboration with physician partners and national experts, these pathways focus on high-prevalence chronic conditions like heart failure, reducing inpatient diagnosis rates and improving medication adherence.
Palliative Care Program: Focuses on providing care in hospice or home settings, improving care satisfaction and reducing hospital admissions.
COPD and Dementia Pilots: Expansion of these pilots is planned for 2026.
Payer Contracting: Negotiations with payer partners for 2026 include reducing Part D exposure, expanding quality incentives, and improving economic terms for Part C.
Membership Strategy: A disciplined approach to membership growth has resulted in a slight year-over-year decline in Medicare Advantage and ACO REACH membership.
Cost Reduction: Operating costs have been reduced by $30 million through centralization, technology implementation, and alignment with PCP partners.
Stars Ratings: Approximately 75% of agilon members are expected to be in 4+ Star plans in 2027, up from 71% in 2026.
Focus on Profitability: agilon is prioritizing profitable growth by taking a disciplined approach to payer contracting and focusing on markets with favorable economics.
Reverse Stock Split: The company anticipates pursuing a reverse stock split and will seek stockholder approval in 2026.
Lower-than-expected in-year RAF contribution: The company faced challenges due to lower-than-expected in-year RAF contribution, which negatively impacted financial performance.
High costs from exited markets: Continued high costs from exited markets have been a financial burden, affecting profitability.
Lower-than-expected risk scores for 2025: Risk scores for 2025 were lower than anticipated, leading to a $150 million negative impact on medical margin.
Membership decline: Medicare Advantage membership declined from 525,000 in Q3 2024 to 503,000 in Q3 2025, partly due to partner exits and a smaller 2025 class.
Elevated medical cost trends: Medical cost trends remain elevated, particularly in inpatient and Part D oncology drugs, impacting financial performance.
Challenges in payer contract negotiations: The company is facing challenges in negotiating favorable payer contracts, which may result in reduced membership if terms are not met.
Exposure to Part D and supplemental benefits: The company continues to face risks from Part D exposure and supplemental benefits, which have been detrimental to capitated economics.
Operational cost structure alignment: Efforts to optimize the cost structure have led to headcount reductions and streamlined operations, but these changes may pose risks to operational efficiency.
Limited claims visibility: The company has limited visibility into paid claims post-quarter close, which complicates accurate forecasting and financial planning.
Potential membership reduction due to contracting strategy: The disciplined approach to payer contracting may lead to reduced membership in 2026, impacting revenue.
2025 Revenue Guidance: Revenue is expected to be in the range of $5.81 billion to $5.83 billion, reflecting membership shifts, improved revenue yield from payer contracts, and lower-than-expected 2025 risk adjustment performance.
2025 Medical Margin Guidance: Full year medical margins are projected to be between negative $5 million to $15 million.
2025 Adjusted EBITDA Guidance: Adjusted EBITDA guidance range is negative $270 million to negative $245 million.
2026 Revenue and Margin Expectations: Revenue growth on a PMPM basis is expected to exceed the 9% CMS final rate notice for 2026, driven by better aligned payer contracts and enhanced quality incentives.
2026 Operating Expense Reduction: Operating expense initiatives are expected to reduce costs by approximately $30 million in 2026.
2026 Membership and Contracting Strategy: Membership may decline in 2026 due to a disciplined approach to payer contracting, focusing on profitability and favorable economics. Some members may transition to care coordination fee arrangements.
2026 Medical Margin and Adjusted EBITDA: Tailwinds such as macro factors, better payer contracts, and cost actions are expected to drive material improvement in medical margin and adjusted EBITDA in 2026.
2026 Cash Position: The company expects to end 2026 with at least $100 million in cash on the balance sheet, including cash held in ACO REACH entities.
2026 Quality and Stars Ratings: Approximately 75% of members are expected to be in 4+ Star plans in 2026, supporting improved payer economics and quality performance.
Clinical Pathways and BOI Program Impact: Programs like heart failure pathways and palliative care are expected to positively contribute to financial results in 2026, with expanded pilots for COPD and dementia.
The selected topic was not discussed during the call.
The earnings call summary presents a mixed picture. While there are strategic plans for 2026, current issues like the negative impact of ACO REACH program changes and unclear management responses create uncertainty. The Q&A section highlights concerns about profitability and contract renewals, but also notes potential improvements in 2026. The market cap suggests moderate volatility, leading to a neutral sentiment as the stock may not significantly move in either direction over the next two weeks.
The earnings call summary reveals a mixed outlook. Financial performance and guidance are moderate, with some positive aspects like stable revenue guidance and quality incentives. However, concerns remain around negative EBITDA, cash usage, and cost pressures. The Q&A session highlights uncertainties in payer relationships and risk adjustments, but also confidence in liquidity and ACO REACH performance. Given the market cap and lack of strong catalysts, the stock price is likely to remain stable, resulting in a neutral prediction.
The earnings report highlights declining membership, revenue, and medical margins, indicating operational and financial challenges. The Q&A session revealed uncertainties regarding Medicare policy, payer negotiations, and drug pricing. Despite some optimism for 2026, the lack of a share repurchase program and absence of clear guidance on key financial metrics further contribute to a negative sentiment. Given the company's small market cap, these factors are likely to result in a stock price decrease of 2% to 8% over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
